Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 9Plasma cell 5Breast 5Thoracic 4Gastrointestinal 4Myeloid 3Genitourinary 3Dermatologic 3CNS 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × tocilizumab × Breast × Clear all
NCT05846789 2026-05-08

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Indiana University

Phase 2 Recruiting
168 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT04871854 2022-11-01

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Beni-Suef University

Phase 2 Completed
100 enrolled
Breast

Breast Neoplasms

NCT03135171 2021-09-10

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

University of Michigan Rogel Cancer Center

Phase 1 Completed
11 enrolled
Breast

Breast Neoplasms

NCT00630292 2010-05-18

Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors

University of North Carolina, Chapel Hill

Phase NA Terminated
6 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡